1.A response to the letter regarding “Minimally invasive surgery for remnant gastric cancer: a single-center retrospective study of treatment outcomes in Japan”
Kenichi IWASAKI ; Edward BARROGA ; Yoichiro KANEKO ; Shohei KONDO ; Toru SAKURAI ; Erika YAMADA ; Masaya ENOMOTO ; Yota SHIMODA ; Kenta KASAHARA ; Hiroaki OSAKABE ; Junichi MAZAKI ; Hiroshi KUWABARA ; Junya OGUMA ; Hiroyuki KOGA ; Akishige KANAZAWA ; Yuichi NAGAKAWA
Journal of Minimally Invasive Surgery 2026;29(2):115-116
2.Minimally invasive surgery for remnant gastric cancer:a single-center retrospective study of treatment outcomes in Japan
Kenichi IWASAKI ; Edward BARROGA ; Yoichiro KANEKO ; Shohei KONDO ; Toru SAKURAI ; Erika YAMADA ; Masaya ENOMOTO ; Yota SHIMODA ; Kenta KASAHARA ; Hiroaki OSAKABE ; Junichi MAZAKI ; Hiroshi KUWABARA ; Junya OGUMA ; Hiroyuki KOGA ; Akishige KANAZAWA ; Yuichi NAKAGAWA
Journal of Minimally Invasive Surgery 2026;29(1):11-21
Purpose:
Surgical resection of remnant gastric cancer (RGC) is technically challenging and difficult. Minimally invasive surgery (MIS) has been adopted for various procedures, but reports of MIS for RGC remain limited. Herein, we report the surgical techniques and short-term outcomes of MIS for RGC.
Methods:
We conducted a retrospective cohort study involving 61 consecutive RGC patients who underwent open or minimally invasive (laparoscopic or robotic) total gastrectomy for potentially curable RGC at our institution (January 1999–August 2025). A propensity scorematched cohort was used for an exploratory evaluation of the safety and efficacy of MIS for RGC, focusing on feasibility rather than superiority over open surgery.
Results:
Of these 61 patients, 53 underwent open surgery and eight underwent MIS gastrectomy for RGC. The median age was 70 years. The cohort comprised 53 men and eight women. The initial procedure was open surgery in 58 patients and MIS in three patients.Propensity score matching showed significantly reduced intraoperative blood loss in the MIS group compared with the open surgery group (39 mL vs. 576 mL, p < 0.05), and significantly longer operation time in the MIS group (352 minutes vs. 297 minutes, p < 0.05). Postoperative hospital stay was significantly shorter in the MIS group (12 days vs. 17 days, p < 0.05). The incidence of postoperative pancreatic fistula was lower in the MIS group, although not significantly different (0% vs. 16.7%).
Conclusion
MIS, including robotic gastrectomy, is feasible and safe for RGC, with potential perioperative benefits requiring multicenter validation.
3.Treatment Experience of Infective Endocarditis after TAVI
Mika TOKUSHIMA ; Hiroyuki MOROKUMA ; Kohei BABA ; Yuki TAKEUCHI ; Nagi HAYASHI ; Kouki JINNOUCHI ; Shugo KOGA ; Junji YUNOKI ; Keiji KAMOHARA
Japanese Journal of Cardiovascular Surgery 2024;53(1):16-19
The patient was an 81-year-old woman who had undergone TAVI (Evolut PRO® 26 mm) for severe aortic stenosis at our hospital approximately 6 months previously. She was discharged from the hospital without any postoperative complications, but at 6 months after the surgery, fever, back pain, and high inflammatory findings were observed. Based on lumbar spine MRI findings, the patient was diagnosed with pyogenic spondylitis and epidural abscess, and drainage surgery was performed. Enterococcus faecalis was identified from a blood culture. MRI of the head showed scattered subacute infarcts in the right frontal lobe, and transthoracic echocardiography revealed hyperintense deposits at the aortic valve leaflet, suggesting vegetation. The diagnosis of PVE was made and medical therapy was initiated. However, the vegetation gradually increased in size and mobility, and a surgical approach was indicated. A surgical procedure was performed through a median sternotomy to remove the prosthetic valve and replace the aortic valve. The postoperative course was good, with no recurrence of infection, and the patient was transferred to another hospital for rehabilitation on the 26th postoperative day. In general, TAVI patients are older and have more comorbidities, and surgery is associated with a higher degree of risk. However, radical surgery should be considered if medical therapy is not effective in PVE after TAVI. We reported a case of surgical aortic valve replacement for PVE after TAVI.
4.Pupillometer-Based Neurological Pupil Index Differential: A Potential Predictor of Post-Stroke Delirium
Kotaro NODA ; Tomotaka TANAKA ; Soichiro ABE ; Ryo USUI ; Misa MATSUMOTO ; Yoshito ARAKAKI ; Hiroyuki KIDA ; Ryoma INUI ; Kaoru KOHAMA ; Kazuo WASHIDA ; Sonu M. M. BHASKAR ; Masatoshi KOGA ; Kazunori TOYODA ; Masafumi IHARA
Journal of Stroke 2024;26(2):321-324
5.Clinical practice guidelines and real-life practice in hepatocellular carcinoma: A Japanese perspective
Hironori KOGA ; Hideki IWAMOTO ; Hiroyuki SUZUKI ; Shigeo SHIMOSE ; Masahito NAKANO ; Takumi KAWAGUCHI
Clinical and Molecular Hepatology 2023;29(2):242-251
Striking advances in systemic therapy for unresectable advanced hepatocellular carcinoma (HCC) have improved the average prognosis of patients with HCC. As a result, the guidelines for the treatment of HCC have changed significantly. However, various issues have emerged in clinical practice. First, there is no established biomarker that can predict response to systemic therapy. Second, there is no established treatment regimen after primary systemic therapy, including combined immunotherapy. Third, there is no established treatment regimen for intermediate-stage HCC. These points make the current guidelines ambiguous. In this review, we present the Japanese guidelines for the diagnosis and treatment of HCC based on the latest evidence; introduce various efforts mainly in Japanese real-life practice to update these guidelines; and present our perspectives on future guidelines.
6.Tacrolimus for ulcerative colitis in children: a multicenter survey in Japan
Tadahiro YANAGI ; Kosuke USHIJIMA ; Hidenobu KOGA ; Takeshi TOMOMASA ; Hitoshi TAJIRI ; Reiko KUNISAKI ; Takashi ISIHIGE ; Hiroyuki YAMADA ; Katsuhiro ARAI ; Atsushi YODEN ; Tomoki AOMATSU ; Satoru NAGATA ; Keiichi UCHIDA ; Yoshikazu OHTSUKA ; Toshiaki SHIMIZU
Intestinal Research 2019;17(4):476-485
BACKGROUND/AIMS: Tacrolimus is effective for refractory ulcerative colitis in adults, while data for children is sparse. We aimed to evaluate the effectiveness and safety of tacrolimus for induction and maintenance therapy in Japanese children with ulcerative colitis.METHODS: We retrospectively reviewed the multicenter survey data of 67 patients with ulcerative colitis aged < 17 years treated with tacrolimus between 2000 and 2012. Patients’ characteristics, disease activity, Pediatric Ulcerative Colitis Activity Index (PUCAI) score, initial oral tacrolimus dose, short-term (2-week) and long-term (1-year) outcomes, steroid-sparing effects, and adverse events were evaluated. Clinical remission was defined as a PUCAI score < 10; treatment response was defined as a PUCAI score reduction of ≥ 20 points compared with baseline.RESULTS: Patients included 35 boys and 32 girls (median [interquartile range] at admission: 13 [11–15] years). Thirty-nine patients were steroid-dependent and 26 were steroidrefractory; 20 had severe colitis and 43 had moderate colitis. The initial tacrolimus dose was 0.09 mg/kg/day (range, 0.05–0.12 mg/kg/day). The short-term clinical remission rate was 47.8%, and the clinical response rate was 37.3%. The mean prednisolone dose was reduced from 19.2 mg/day at tacrolimus initiation to 5.7 mg/day at week 8 (P< 0.001). The adverse event rate was 53.7%; 6 patients required discontinuation of tacrolimus therapy.CONCLUSIONS: Tacrolimus was a safe and effective second-line induction therapy for steroid-dependent and steroid-refractory ulcerative colitis in Japanese children.
Adult
;
Asian Continental Ancestry Group
;
Biological Factors
;
Child
;
Colectomy
;
Colitis
;
Colitis, Ulcerative
;
Female
;
Humans
;
Immunologic Factors
;
Japan
;
Prednisolone
;
Remission Induction
;
Retrospective Studies
;
Tacrolimus
;
Ulcer
7.A Case of Central Diabetes Insipidus Who Underwent Open Heart Surgery
Shizuka Yaita ; Ryo Noguchi ; Keiji Kamohara ; Junji Yunoki ; Hiroyuki Morokuma ; Shugou Koga ; Atuhisa Tanaka ; Koujiro Furukawa ; Shigeki Morita
Japanese Journal of Cardiovascular Surgery 2016;45(6):277-280
Central diabetes insipidus (CDI) is a disease that caused by insufficient or no anti-diuretic hormone (ADH) secretion from the posterior pituitary, which results in an increase in urine volume. CDI is controlled with ADH supplementation thereby reducing urine output and correcting electrolyte imbalance. However, reports on perioperative management for CDI patient are scarce, especially for patients who underwent cardiac surgery. We herein report our experience of the management of a CDI patient who underwent surgery for valvular heart disease.
The case is a 72-year-old woman who developed secondary CDI after pituitary tumor removal. She had been controlled with orally administered desmopressin acetate hydrochloride. She underwent aortic valve replacement and mitral valve repair for severe aortic, and moderate mitral regurgitation. Immediately after surgery, we started vasopressin div, which yielded good urine volume control. However, once we started to switch vasopressin to oral desmopressin administration, the control became worse. We thus made a sliding scale for subcutaneous injection of vasopressin every 8 h according to the amount of urine output, which resulted in good control. Overlapping administration of vasopressin and oral desmopressin between postoperative day 12 and 17 resulted in successful transition. The patient was discharged with oral desmopressin administration. Management with sliding scale for vasopressin subcutaneous injection after surgery was useful in controlling a CDI patient who underwent major cardiac surgery.
8.Absorption of Folic Acid from Potato Chips in Humans
Katsuyuki ISHIHARA ; Akiko SEKIYA ; Kazuo UEBABA ; Takuya KAWASHIMA ; Yusuke NAKADE ; Fenghao XU ; Hiroyuki MUGITA ; Rui SAKUMA ; Hidenori KOGA ; Katsushi KAWABATA ; Nobutaka SUZUKI
Japanese Journal of Complementary and Alternative Medicine 2014;11(1):35-40
Folic acid contained in potato (Solanum tuberosum L.) tubers is concentrated in potato chips by dehydration during frying. It is a vitamin recommended to young women which helps protect fetus from congenital disease. Additionally, folic acid can lower plasma homocysteine concentrations, a known independent risk factor for cardiovascular disease. This study was designed to determine whether the dietary consumption of potato chips affect serum folic acid concentration and plasma homocysteine concentration in human subjects. Results showed a significant increase in serum concentrations of folate 1, 3, and 6 hours after ingestion. Vitamin B6, on the other hand, increased significantly after 3 hours of intake. In contrast, plasma homocysteine concentration decreased significantly 6 hours after ingestion. These results suggest that potato chips would be a good dietary source of folic acid for humans.


Result Analysis
Print
Save
E-mail